Salim Yazji
Directeur Technique/Scientifique/R&D chez ONCTERNAL THERAPEUTICS, INC.
Fortune : 53 064 $ au 30/04/2024
Profil
Salim Yazji is the founder of Elpida Therapeutics and Ajuta Therapeutics, Inc. He currently holds the position of Director at Versatope Therapeutics, Inc. and Chief Medical Officer at Oncternal Therapeutics, Inc. His former positions include Vice President-Global Therapeutics at Baxalta, Inc., Chief Medical Officer & Executive Vice President at Calimmune, Inc., and Chief Medical Officer at PMV Pharmaceuticals, Inc. Yazji holds a doctorate degree from Pavlov First Saint Petersburg State Medical University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 14/02/2024 | 6 432 ( 0,22% ) | 53 064 $ | 30/04/2024 |
Postes actifs de Salim Yazji
| Sociétés | Poste | Début |
|---|---|---|
| ONCTERNAL THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 17/05/2021 |
Versatope Therapeutics, Inc.
 Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | Directeur/Membre du Conseil | 01/04/2019 |
| Elpida Therapeutics | Fondateur | - |
Anciens postes connus de Salim Yazji
| Sociétés | Poste | Fin |
|---|---|---|
| BAXALTA INC | Corporate Officer/Principal | - |
| PMV PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
Calimmune, Inc.
 Calimmune, Inc. BiotechnologyHealth Technology Calimmune, Inc. operates as a clinical-stage biotechnology company. The firm offers Cal-1, a gene-based stem cell therapy to protect individuals infected with HIV from progressing to AIDS. The company was founded by David Baltimore, Inder M. Verma, Irvin Chen and Louis Breton in 2006 and is headquartered in Tucson, AZ. | Directeur Technique/Scientifique/R&D | - |
| Ajuta Therapeutics, Inc. | Directeur Général | - |
Formation de Salim Yazji
| Pavlov First Saint Petersburg State Medical University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PMV PHARMACEUTICALS, INC. | Commercial Services |
| ONCTERNAL THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Baxalta, Inc.
 Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
Calimmune, Inc.
Calimmune, Inc. BiotechnologyHealth Technology Calimmune, Inc. operates as a clinical-stage biotechnology company. The firm offers Cal-1, a gene-based stem cell therapy to protect individuals infected with HIV from progressing to AIDS. The company was founded by David Baltimore, Inder M. Verma, Irvin Chen and Louis Breton in 2006 and is headquartered in Tucson, AZ. | Health Technology |
Versatope Therapeutics, Inc.
Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | Health Technology |
| Ajuta Therapeutics, Inc. | |
| Elpida Therapeutics |
